Please provide your email address to receive an email when new articles are posted on . The introduction of additional neflamapimod in an open-label extension led to significant clinical improvements.

And I think a lot of what we’re going to be seeing in the next, let’s say, 12 to 24 months, are people realizing that whoever has the strongest, most holistic data set is going to be in the best ...

Last year, Fiio introduced the DM13, a portable CD player with modern features (such as USB-C charging and built-in Bluetooth) and priced at $150, making it a relatively affordable excuse to revisit ...

Sealed Air's (SEE) sale to CD&R could see some investor pushback as the price is likely below expectations, according to a Wolfe Research analyst. "We sense that the deal value is below most buy-side ...

Nov 17 (Reuters) - U.S. packaging company Sealed Air Corp (SEE.N), opens new tab said on Monday it agreed to be bought by private equity firm CD&R for $10.3 billion, including debt, in a deal that ...

Multi-Color Corp.’s earnings were hit hard by lower customer demand in the third quarter as the label making firm’s debt obligations grow more daunting, according to people familiar with the situation ...

The FDA has approved belantamab mafodotin (Blenrep, GlaxoSmithKline) in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma (R/R MM) in adults after at least two ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

This ballot initiative asks voters to increase taxes on wealthier Coloradans to raise an additional $95 million to fully fund the Healthy School Meals for All program, which provides free breakfast ...

Steve Macfarlane consults for Eisai, Janssen and Eli Lilly, and participated as a researcher in the donanemab study. Eisai manufactures lecanemab, while donanemab is owned by Eli Lilly. Dementia is a ...

Teclistamab showed high response rates in older, heavily pretreated multiple myeloma patients in a community setting, comparable to clinical trial results. The study reported 74% overall response rate ...